Researchers found acidic pH microenvironments in tumors promote autophagy, allowing cancer cells to survive and proliferate. The study suggests a potential therapeutic strategy based on inhibiting autophagy, which could introduce novel treatment options for tumor progression.
A recent meta-analysis by researchers at Moffitt Cancer Center found that breast cancer patients who received chemotherapy had slight cognitive impairments in verbal and visuospatial abilities. The study suggests that these deficits can be managed through awareness and compensatory strategies, improving daily life for affected individu...
Researchers at Moffitt Cancer Center have identified PHF20 as a novel transcriptional factor that regulates gene P53, a crucial gene for normal cell growth and tumor suppression. The study found that PHF20 directly interacts with p53 and stabilizes it, allowing for its activation in response to DNA damage.
Researchers at Moffitt Cancer Center report on immune-related adverse events associated with ipilimumab and tremelimumab, two anti-CTLA-4 antibodies used in treating metastatic melanoma. The study highlights the importance of early recognition and management of these side effects to improve treatment outcomes.
Researchers have validated a radiosensitivity molecular signature that can predict clinical outcomes in patients treated with radiation therapy for breast cancer. The technology, called RSI, identifies radiosensitivity and radioresistance, opening the door to biologically guided radiation therapy.
Researchers found that pre-test genetic counseling decreases distress in before-surgery patients, while improving informed decision-making in after-surgery patients. Both groups showed increased cancer knowledge following the counseling.
Researchers at Moffitt Cancer Center discovered a mechanism by which cancer cells hijack histone regulation to promote growth and survival. Lower levels of histone protein H2B aid in suppressing core histone gene transcription, leading to unchecked cell growth.
A recent study found that 86% of non-smokers and 57% of smokers supported the ban, with many smokers expressing interest in quitting. Despite high demand for cessation services, only a few employees took advantage of them.
Researchers at Moffitt Cancer Center found that inhibiting signal transducer and activator of transcription 3 (STAT3) can harness the immune system to eradicate residual malignant cells in drug-resistant mantle cell lymphoma. This strategy could provide a new approach for patients with therapy-resistant MCL.
A recent study at Moffitt Cancer Center has validated a rare genetic variant associated with an increased risk of glioma, the most common and lethal type of brain tumor. The study found that individuals carrying this variant had a 3.5 times higher risk of developing glioma, but also experienced a 50% reduction in death rates
Researchers found associations between certain types of cutaneous human papillomavirus (HPV) and squamous cell carcinoma (SCC). The study investigated five HPV genera and found significant associations between HPV 10 in genus alpha and SCC, as well as beta HPV types 5, 8, 17, and 24.
Researchers at Moffitt Cancer Center tested a 2-drug combination of sirolimus and tacrolimus to prevent acute grades of graft vs. host disease after blood cell transplantation, finding it more effective than another combination in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD.
Researchers at H. Lee Moffitt Cancer Center found a synergy between sun exposure and cutaneous HPV infection in developing non-melanoma skin cancers like basal cell carcinoma and squamous cell carcinoma. People with low melanin production, such as those with light skin, are more susceptible to these risks.
Researchers at Moffitt Cancer Center and colleagues have tested deferasirox as a treatment for myelodysplastic syndrome (MDS), a blood-related malignancy that affects the ineffective production of blood cells. Deferasirox reduced iron levels by 23% in 53% of patients, showing promising results for this type of cancer.
Researchers at Moffitt Cancer Center say cancer's evolutionary principles hold the key to thwarting emergence of drug resistance. By anticipating and adapting to environmental forces, they propose developing 'adaptive therapies' to improve outcomes.
A new immune approach to fighting some cancers has shown promise, with 20-25% of heavily pre-treated patients responding to BMS-936558. The treatment specifically blocks programmed cell death 1 (PD-1), a key immune checkpoint receptor.
Researchers at H. Lee Moffitt Cancer Center & Research Institute found a multimedia psychoeducational intervention more effective in changing patients' perceptions and negative attitudes toward clinical trials than standard educational literature.
Researchers found African-American survivors have unmet needs in dealing with fears of recurrence, while spouses report concerns about stress and anxiety. The study highlights the importance of culturally appropriate interventions, including improved communication and symptom management for better outcomes.
Researchers at Moffitt Cancer Center have developed a synthetic vaccine that induces tumor clearance in 100% of mice with HPV16-induced tumors. The vaccine, called TriVax-HPV, generates large numbers of cytotoxic T-cells targeting viral proteins, offering an alternative to conventional therapies for cervical cancer.
Researchers build 'spaghetti models' of cancer progression using mathematical models, predicting tumor growth, response to treatments, and risk of recurrence. This approach combines clinical imaging with biological experiments and mathematical modeling to develop patient-specific medicine.
Moffitt Cancer Center researchers identified 39 tyrosine kinases in sarcoma cells, which could drive tumor growth and survival. These enzymes were found to be expressed in multiple tumors, potentially limiting the effectiveness of targeted agents.
Researchers at Moffitt Cancer Center found that adolescents newly diagnosed with cancer have strong concerns about their ability to have children as cancer survivors. Parents often inaccurately relayed their child's reproductive concerns and underestimated their daughters' desires for future parenthood.
Researchers at Moffitt Cancer Center have found a new way to overcome resistance to drugs that target the BRAF gene mutation in melanoma. The study, led by Jeffrey S. Weber and Keiran S. Smalley, showed that an inhibitor called XL888 can restore effectiveness in patients who have developed resistance to existing treatments.
Researchers at Moffitt Cancer Center are developing 'designer lymph nodes' that use gene-modified cells to produce a pre-planned immunologic response for cancer patients. These innovative nodes aim to rebuild and augment the immune system, overcoming dysfunction caused by tumors or treatments.
A Moffitt researcher has received a $100,000 grant from General Electric to develop a genetic tool that can identify an individual's predisposition to developing or resisting breast cancer metastasis. The study aims to evaluate inherited changes in DNA predictive of and identify risk for developing or resisting breast cancer metastasis.
Researchers at Moffitt Cancer Center found that breast cancer survivors who underwent chemotherapy and/or radiation therapy performed worse on cognitive tests than those who did not have cancer. The study's findings suggest long-term cognitive effects of these therapies need further investigation.
Researchers found that two-thirds of breast cancer survivors experience moderate-level cancer worry three years after treatment, with fatigue and risk perception being significant factors. The study aimed to identify characteristics associated with cancer worry, which can impact health behaviors.
Researchers validated two new staging classification systems for neuroendocrine pancreatic tumors, finding that advancing stage correlates with increasing risk of metastatic relapse after surgery. The study also showed that small, low-grade tumors have exceptionally low metastatic potential.
Researchers at Moffitt Cancer Center found no link between body mass index (BMI) and post-surgical complications or survival rates among esophageal cancer patients. The study, published in the Journal of Gastrointestinal Surgery, included 303 patients treated with chemotherapy, radiation, and surgery.
Researchers found that certain genetic mutations in acute myeloid leukemia patients predicted improved outcomes when treated with high-dose induction chemotherapy. Mutational profiling could help identify distinct subgroups of patients who may benefit from dose-intensified therapy.
Researchers at Moffitt Cancer Center found that 38% of lung cancer patients suffer from depression, with greater stigma levels related to higher depressive symptoms. Psychotherapeutic approaches may help alleviate or prevent depression by altering perceptions of stigma.
Researchers found that smoking restored depleted self-control resources in smokers, improving their mood and performance on frustrating tasks. This study suggests that nicotine can be a maladaptive way to cope with stress, and alternative strategies like relaxation or sugary drinks may be healthier options.
Researchers found a high response rate of 56% and median survival of nearly 16 months for patients with metastatic melanoma treated with vemurafenib. This was higher than other therapies, with rapid responses and common toxic effects, but also potential resistance mechanisms under investigation.
A combination therapy of dendritic cell implants and radiotherapy was found to be effective in inducing tumor-specific immune responses in 52.9% of trial patients with high-risk soft tissue sarcomas. The treatment resulted in dramatic increases in immune T cells in the tumors, leading to significant clinical benefits.
A new study by researchers at H. Lee Moffitt Cancer Center has found that the XL888 inhibitor can prevent resistance to chemotherapy drug vemurafenib in melanoma patients, leading to induced apoptosis response and tumor regression. The study suggests a novel approach to managing drug resistance using broadly targeted strategies.
Researchers evaluated a teaching program for breaking bad news to patients, finding that medical students reported improved comfort in addressing difficult topics. The program involved videotaped sessions with standardized patients and post-interview discussions, which were found to be highly beneficial.
A recent study found that female cancer survivors have poorer health behaviors than women without a cancer history, including higher rates of smoking and weight gain. Researchers hope to capitalize on these 'teachable moments' to encourage healthier lifestyles among cancer survivors.
IKBKE is induced by tobacco carcinogens and mediates tobacco action in promoting lung cancer cell survival. Knocking down IKBKE sensitizes cells to chemotherapy, suggesting a therapeutic role for targeting this pathway.
The partnership aims to reduce cancer health disparities in Hispanic populations through outreach education projects and pilot research studies. The collaboration has already learned valuable lessons, including the importance of a patient-centered approach and culturally specific dissemination routes for information.
A study by researchers at H. Lee Moffitt Cancer Center and colleagues identified 27 genes involved in inflammation as related to ovarian cancer risk. The study found that variants in five of these genes, such as IL1A, were associated with lower ovarian cancer risk.
Researchers analyzed past studies on cancer-related pain reduction and found that psychosocial interventions can significantly improve cancer patients' pain severity. Skill-based interventions and educational approaches were most successful in reducing pain and its impact on daily life.
Researchers discovered that the interaction between CD4 T cells and myeloid-derived suppressor cells (MDSC) can inhibit T-cell function, while CD8 T cells are not affected. The study suggests a potential mechanism for controlling dysregulated immune responses in cancer.
Researchers have developed targeted, fluorescent molecular imaging probes that can non-invasively detect breast cancer lymph node metastases, improving breast cancer staging and prognosis. CAIX and CAXII cell surface markers are highly expressed in breast cancer lymph node metastases.
A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The signature was able to distinguish between low and high malignancy risk groups, correlating with good or poor overall survival rates.
Researchers at Moffitt Cancer Center found that fibroblasts play a significant role in melanoma tumor growth and progression. The study also revealed that fibroblasts contribute to drug resistance and the 'flare' response, where tumors exhibit enhanced metabolism after targeted therapy is stopped.
Researchers at Moffitt Cancer Center have identified a chemical disrupter of the Rb-Raf-1 interaction, which may be vulnerable to targeting to prevent cancer cell proliferation and tumor growth. The study found that this disruption can limit metastasis in test mice, suggesting a potential new approach for combating metastatic disease.
Researchers found a strong association between smoking and squamous cell carcinoma in women, with increased risk seen with higher cigarette consumption. Smoking history was more strongly linked to SCC in women than men, with a four-fold increase in those who had smoked for 20 years or more.
A follow-up study by Moffitt Cancer Center researchers found that patients who received chemotherapy for breast cancer may experience prolonged fatigue years after treatment. This contradicts prior research and has important implications for patient education and fatigue monitoring during follow-up.
Researchers at Moffitt Cancer Center found MK1775 effective in treating sarcoma cells, inducing apoptosis and causing cell death, regardless of p53 mutation status. The study suggests that Wee1 inhibition by MK1775 may represent a novel approach in treating sarcomas.
Researchers at Moffitt Cancer Center found that men are less willing to be screened for cancer despite having higher mortality rates. The study suggests that better health and cancer screening promotion among men can improve existing practices.